Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review.
Gastroenterology and hepatology from bed to bench. · 01.01.2024 · 17 (3) · 225-240
DOI: 10.22037/ghfbb.v17i3.2978 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Gastroenterology and hepatology from bed to bench., erschienen am 01.01.2024. Verfasst von Milad Khabbazpour und 6 weiteren Autor:innen. Beteiligte Einrichtung: Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
A systematic review was conducted to summarize the methylated circulating tumor DNA (ctDNA) markers reported over the last decade for early detection of colorectal cancer (CRC) and to identify the main technical challenges that are impeding their clinical implementation.
Background
CRC is a major cause of cancer deaths worldwide, but early detection is key for successful treatment. Non-invasive methods such as methylated ctDNA testing show promise for improving detection and monitoring of CRC.
Methods
A comprehensive search was performed using Web of Science, PubMed, and Scopus up to December 30, 2023, limited to articles published in the last 10 years (after 2012), while including advanced adenoma/stage 0 or stage I/II samples in biomarker validation.
Results
After identifying 694 articles, removing duplicates and screening titles, abstracts, and full texts, a total of 62 articles were found to meet the inclusion criteria. Among the single biomarkers, MYO1-G, SEPT9, SDC2, and JAM3 revealed the highest sensitivity for polyps and stage I/II CRC. For multi-biomarkers with suitable sensitivity, combinations of SFRP1, SFRP2, SDC2, PRIMA1, or ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, VIM or ZFHX4, ZNF334, ELOVL2, UNC5C, LOC146880, SFMBT2, GFRA1 were identified for polyps and stage I/II CRC.
Conclusion
Enhancing sensitivity and specificity of molecular screening methods is crucial for improving CRC detection. Identifying a select few valuable biomarkers is key to reducing costs, despite challenges posed by low ctDNA levels in plasma, particularly in early-stage cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
- Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
- Department of Cell and Molecular Biology and Microbiology, Faculty of biological science and technology, University of Isfahan, Isfahan, Iran.
- Vali-e-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Khabbazpour, M., Tat, M., Karbasi, A., Abyazi, M. A., Khodadoustan, G., Heidary, Z., & Zaki-Dizaji, M. (2024). Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review. Gastroenterology and hepatology from bed to bench., 17(3), 225-240. https://doi.org/10.22037/ghfbb.v17i3.2978
Vancouver
Khabbazpour M, Tat M, Karbasi A, Abyazi MA, Khodadoustan G, Heidary Z, et al. Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review. Gastroenterology and hepatology from bed to bench.. 2024;17(3):225-240. doi:10.22037/ghfbb.v17i3.2978
BibTeX
@article{Khabbazpour2024,
author = {Khabbazpour, Milad and Tat, Masoud and Karbasi, Ashraf and Abyazi, Mohammad Ali and Khodadoustan, Ghazal and Heidary, Zohreh and Zaki-Dizaji, Majid},
title = {Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review},
journal = {Gastroenterology and hepatology from bed to bench.},
year = {2024},
volume = {17},
number = {3},
pages = {225--240},
doi = {10.22037/ghfbb.v17i3.2978}
}
EUVIMED